Kristen Fortney, BioAge Labs CEO
September 26, 2024 03:11 AM EDT
Financing
Startups

Next-gen obe­si­ty biotech BioAge Labs to raise $198M in IPO

Kyle LaHucik

Senior Reporter

A Cal­i­for­nia biotech that be­gan as an an­ti-ag­ing com­pa­ny, then li­censed an Am­gen heart fail­ure drug for $1 mil­lion up­front and re­pur­posed it as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

ARCH, biotech's star slug­ger, snags an­oth­er $3B for 13th fund

Up­dat­ed: FDA ad­comm votes to lim­it Op­di­vo, Keytru­da use in stom­ach, esophageal can­cers based on key bio­mark­er

Flag­ship launch­es start­up to de­sign and make lipid nanopar­ti­cles for ge­net­ic med­i­cines

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times